I'm really optimistic about CVKD given its solid financials, strategic partnerships, and significant market potential. With a price target of $45 from Noble Financial, there's a great opportunity here to invest at around $16 and catch some upward momentum in the coming weeks.

I'm really bullish on CVKD right now. With its low market cap and FDA fast track designation, it seems like a solid opportunity to ride the momentum as it heads towards FDA approval. The collaboration with Abbott adds further credibility to the play, making it worth considering for the near future.

I'm really bullish on CVKD due to the FDA Fast-Track and Orphan Drug status for tecarfarin. This positions the company to potentially capture a significant share of a $2B market, especially in underserved areas, which could lead to major revenue growth.

I'm really optimistic about Cadrenal's potential with Tecarfarin, especially with the FDA fast-track and Phase 3 trials showing promise. If these trials turn out well, I believe CVKD is set to soar, making this a solid pick for a swing trade.